Related Experiment Video
Updated: Feb 7, 2026
10:02
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
2.6K
Immunotherapy in Glioblastoma
Jessica A Wilcox1, Rohan Ramakrishna2, Rajiv Magge1
1Department of Neurology, Weill Cornell Medical College, New York, New York, USA.
World Neurosurgery
|July 28, 2018
Summary
Glioblastoma (GBM) is challenging due to immune suppression. Immunotherapies show promise but require biomarker identification and better management of side effects for glioblastoma treatment.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Therapy
Background:
- Glioblastoma (GBM) exhibits significant immune suppression, hindering conventional treatments.
- The immunosuppressive tumor microenvironment in GBM presents a therapeutic target.
Purpose of the Study:
- To review current immunotherapies investigated for glioblastoma treatment.
- To discuss the potential and challenges of immunotherapy in managing glioblastoma.
Main Methods:
- Review of ongoing immunotherapy strategies for glioblastoma.
- Analysis of mechanisms of immune evasion in glioblastoma.
- Exploration of predictive biomarkers and adverse event management.
Main Results:
- Several immunotherapies are under investigation, including immune checkpoint inhibitors, vaccines, T-cell therapies, and oncolytic viruses.
- The efficacy of immunotherapy in glioblastoma remains to be fully established.
- Identifying predictive biomarkers is crucial for treatment success.
Conclusions:
- Glioblastoma immunotherapy holds potential but requires further research.
- Optimizing patient selection through biomarkers and managing immune-related adverse effects are key to realizing immunotherapy's full potential in glioblastoma.
